CINECA IRIS Institutional Research Information System

PETRINI, MARIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 41.075
EU - Europa 17.722
AS - Asia 7.232
AF - Africa 573
SA - Sud America 196
OC - Oceania 37
Continente sconosciuto - Info sul continente non disponibili 13
Totale 66.848
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 37.745
IT - Italia 6.353
SE - Svezia 3.547
CN - Cina 3.397
CA - Canada 3.293
BG - Bulgaria 1.622
DE - Germania 1.585
SG - Singapore 1.511
TR - Turchia 1.038
PL - Polonia 997
GB - Regno Unito 939
UA - Ucraina 786
VN - Vietnam 748
FI - Finlandia 622
CH - Svizzera 329
RU - Federazione Russa 321
CI - Costa d'Avorio 312
HK - Hong Kong 219
IN - India 199
AT - Austria 166
BR - Brasile 157
FR - Francia 143
BE - Belgio 142
SN - Senegal 119
NG - Nigeria 84
JP - Giappone 40
MX - Messico 31
NL - Olanda 31
AU - Australia 30
CZ - Repubblica Ceca 25
BJ - Benin 24
EG - Egitto 18
IE - Irlanda 17
ES - Italia 15
GR - Grecia 15
KR - Corea 15
EU - Europa 12
ID - Indonesia 10
HU - Ungheria 9
IQ - Iraq 9
IR - Iran 9
PT - Portogallo 9
DK - Danimarca 8
EC - Ecuador 8
IL - Israele 7
NZ - Nuova Zelanda 7
PK - Pakistan 7
AR - Argentina 6
CL - Cile 6
LT - Lituania 6
BO - Bolivia 5
EE - Estonia 5
RO - Romania 5
RS - Serbia 5
ZA - Sudafrica 5
CO - Colombia 4
MA - Marocco 4
TW - Taiwan 4
BD - Bangladesh 3
HR - Croazia 3
IS - Islanda 3
LU - Lussemburgo 3
MY - Malesia 3
PE - Perù 3
SA - Arabia Saudita 3
BA - Bosnia-Erzegovina 2
BY - Bielorussia 2
MD - Moldavia 2
MU - Mauritius 2
NI - Nicaragua 2
NP - Nepal 2
PA - Panama 2
PY - Paraguay 2
TH - Thailandia 2
TN - Tunisia 2
UY - Uruguay 2
UZ - Uzbekistan 2
VE - Venezuela 2
A1 - Anonimo 1
AL - Albania 1
ET - Etiopia 1
GE - Georgia 1
GL - Groenlandia 1
GY - Guiana 1
JM - Giamaica 1
JO - Giordania 1
KE - Kenya 1
LI - Liechtenstein 1
LV - Lettonia 1
MN - Mongolia 1
MT - Malta 1
NO - Norvegia 1
OM - Oman 1
SC - Seychelles 1
Totale 66.848
Salva come PNG Salva come JPEG
Città #
Woodbridge 5.306
Ann Arbor 4.256
Fairfield 3.497
Houston 3.300
Chandler 2.923
Santa Clara 2.474
Serra 2.348
Montreal 2.302
Ashburn 1.930
Milan 1.660
Sofia 1.618
Seattle 1.540
Wilmington 1.255
Beijing 1.217
Cambridge 1.148
Jacksonville 1.112
Ottawa 949
New York 922
Singapore 819
Princeton 754
Izmir 735
Boardman 731
Lawrence 614
Medford 576
Nanjing 518
Des Moines 393
Dearborn 379
Dong Ket 329
Bern 319
Abidjan 312
Florence 285
Istanbul 280
Nanchang 235
Lancaster 223
Hong Kong 203
Jüchen 197
San Diego 195
Rome 170
Redwood City 159
Vienna 154
London 152
Boulder 151
Brussels 141
Pisa 137
Bremen 136
Kunming 133
Dakar 119
Shenyang 117
Hebei 104
Frankfurt am Main 100
Changsha 89
Washington 88
Ogden 87
Lagos 84
Los Angeles 81
Hefei 80
Jiaxing 79
Fuzhou 76
Shanghai 73
Westminster 73
Tianjin 65
Chicago 64
Norwalk 62
Falls Church 61
Pune 61
Nürnberg 52
Hangzhou 51
Quanzhou 46
Orange 45
Guangzhou 44
Auburn Hills 40
Düsseldorf 33
Phoenix 32
Detroit 30
Dallas 29
Jinan 29
Lanzhou 29
Alessandria 26
Wuhan 26
Cotonou 24
Chengdu 23
Changchun 21
San Jose 21
San Francisco 20
Marseille 19
Toronto 19
Helsinki 18
Tokyo 18
Verona 18
Zhengzhou 18
Hyderabad 16
Tappahannock 16
Capannori 15
Costa Mesa 15
Council Bluffs 14
Indiana 14
Warsaw 14
Monza 13
São Paulo 13
Baotou 12
Totale 51.623
Salva come PNG Salva come JPEG
Nome #
EFFICACY AND TOXICITY PROFILES OF LOW-DOSE THALIDOMIDE AS MAINTENANCE THERAPY IN MULTIPLE MYELOMA PATIENTS AFTER DOUBLE OR TRIPLE AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION. 3.366
CD57 expression on lymphoma microenvironment as a new prognostic marker related to immune dysfunction 216
Atypical APL including multiple translocations and abnormal response to micronuclei induction test 212
Acute myeloid leukemia and follicular lymphoma after very low dose radioiodine therapy for thyroid diseases 195
1,25(OH)2D3 and TPA in vitro activity on B-CLL. 194
Evaluation of the MDR1, ABCG2, Topoisomerases IIalpha and GSTpi gene expression in patients affected by aggressive mantle cell lymphoma treated by the R-Hyper-CVAD regimen. Leuk Lymphoma 194
CD45 expression in low-grade B-cell non-Hodgkin's lymphomas 193
Bone tissue engineering: Natural origination or synthetic polymeric scaffolds? 187
How Nanotechnology Can Really Improve the Future of Orthopedic Implants and Scaffolds for Bone Defects 185
Alternating chemotherapy regimen (P-VABEC) for intermediate and high-grade non-Hodgkin's lymphoma of the middle aged and elderly. 185
Bone marrow infiltration in B-cell non-Hodgkin's lymphomas: comparison between flow cytometry and bone marrow biopsy, RECENTI PROGRESSI IN MEDICINA 178
Barium Titanate Nanoparticles: Highly Cytocompatible Dispersions in Glycol-chitosan and Doxorubicin Complexes for Cancer Therapy. 178
Acute myeloid leukemia and follicular lymphoma after very low dose radioiodine therapy for thyroid diseases 177
Kinetics of hematogones in bone marrow samples from patients with non-Hodgkin lymphomas treated with rituximab-containing regimens: a flow cytometric study 176
Identification of miRSNPs associated with the risk of multiple myeloma 176
Is binding of vitamin D binding protein related to cell differentiation? 175
Investigation of interactions between poly-L-lysine-coated boron nitride nanotubes and C2C12 cells: up-take, cytocompatibility, and differentiation 175
Mesenchymal cells inhibit expansion but not cytotoxicity exerted by gamma-delta T cells 175
EVALUATION OF RESISTANCE INDEX OF SEVERAL ANTICANCER AGENTS ON PARENTAL AND RESISTANT P-388 CELL LINES 172
Plasticity of human dental pulp stromal cells with bioengineering platforms: A versatile tool for regenerative medicine. 171
Nonpegylated liposomal doxorubicin (MyocetTM) combination (R-COMP) chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL): results from the phase II EUR018 trial 170
Human autologous plasma-derived clot as a biological scaffold for mesenchymal stem cells in treatment of orthopedic healing. 170
New approaches for imaging and therapy of solid cancer 169
INDOMETHACIN INHIBITION OF BONE-MARROW GRANULOCYTE RELEASE INTO PERIPHERAL-BLOOD 168
Complex translocation t(3;9;22)(q21;q34;q11) at diagnosis is a negative prognostic index in chronic myeloid leukemia. 168
Preparation of stable dispersion of barium titanate nanoparticles: Potential applications in biomedicine 168
Mesenchymal Stromal Cell Culture and Delivery in Autologous Conditions: A Smart Approach for Orthopedic Applications 168
Pore Size Distribution and Blend Composition Affect In Vitro Prevascularized Bone Matrix Formation on Poly(Vinyl Alcohol)/Gelatin Sponges 168
La storia della Facoltà di Medicina e Chirurgia 167
IN THE CHRONIC MYELOID LEUKEMIA THE SALIVARY PROTEOMICS RECAPITULATES SOME ASPECTS OF THE LEUKEMIC STEM CELL. LA CELLULA STAMINALE LEUCEMICA E LA PROTEOMICA SALIVARE: IL MODELLO DELLA LEUCEMIA MIELOIDE CRONICA 167
Growing bone tissue-engineered niches with graded osteogenicity: an in vitro method for biomimetic construct assembly 167
Novel biological/biohybrid prostheses for the ossicular chain: fabrication feasibility and preliminary functional characterization 167
B-cell acute lymphoblastic leukemia with t(4;11)(q21;q23) in a young woman: evolution into mixed phenotype acute leukemia with additional chromosomal aberrations in the course of therapy. 166
Boron nitride nanotubes and primary human osteoblasts: in vitro compatibility and biological interactions under low frequency ultrasound stimulation 165
MESENCHYMAL CELLS INHIBIT IL2 AND ZOLENDRONATE-INDUCED ?/d T-LYMPHOCYTES 164
Response to chemotherapy and tandem autologous transplantation of multiple myeloma patients and GSTP1 and TYMS polymorphisms 163
Constitutive expression of pluripotency-associated genes in mesodermal progenitor cells (MPCs) 163
Inferential mining for reconstruction of 3D cell structures in Atomic Force Microscopy imaging 163
Identification and purification of mesodermal progenitor cells from human adult bone marrow. 161
5-HT2a inhibitors for progressive multifocal leukoencephalopathy: old drugs for an old disease 161
Treatment of oral mucositis in hematologic patients undergoing autologous or allogeneic transplantation of peripheral blood stem cells: a prospective, randomized study with a mouthwash containing Camelia Sinensis leaf extract 161
CHEMOIMMUNOTHERAPY REGIMEN OF FLUDARABINE, CYCLOPHOSPHAMIDE, AND RITUXIMAB FOLLOWED BY ALEMTUZUM- AB AS INITIAL THERAPY FOR CHRONIC LYMPHOCYTIC LEUKAEMIA: A VALID APPROACH FOR ERADICATION OF MINIMAL RESIDUAL DISEASE 160
Arsenic trioxide and ascorbic acid interfere with the BCL2 family genes in patients with myelodysplastic syndromes: an ex-vivo study. 160
Could age modify the effect of genetic variants in IL6 and TNF-a genes in multiple myeloma? 160
Infliximab treatment of grade IV skin acute graft versus host disease 158
Quantitative molecular monitoring of BCR-ABL and MDR1 transcripts in patients with chronic myeloid leukemia during Imatinib treatment 158
Development of tissue-engineered substitutes of the ear ossicles: PORP-shaped poly(propylene fumarate)-based scaffolds cultured with human mesenchymal stromal cells. 157
Vorinostat and bortezomib significantly inhibit WT1 gene expression in MO7-e and P39 cell lines 157
Comprehensive investigation of genetic variation in the 8q24 region and multiple myeloma risk in the IMMEnSE consortium. 157
Specific integrin expression is associated with podosome-like structures on mesodermal progenitor cells. 157
Carboxy-terminal fragment of osteogenic growth peptide regulates myeloid differentiation through RhoA 155
β-Cell inflammation in human type 2 diabetes and the role of autophagy 155
Evaluation of the MDR1, ABCG2, Topoisomerases IIalpha and GSTpi gene expression in patients affected by aggressive mantle cell lymphoma treated by the R-Hyper-CVAD regimen 154
Genetics and molecular epidemiology of multiple myeloma: the rationale for the IMMEnSE consortium (review). 154
Glycosylation interference on RhoA activation: focus on G-CSF 154
Oral cyclophosphamide therapy for patients with residual or relapsed indolent-type lymphoma after initial treatment for aggressive lymphomas. A sub-group of patients with apparent transformed indolent lymphoma. 152
Treatment schedules for 5-HT2A blocking in progressive multifocal leukoencephalopathy using risperidone or ziprasidone 152
Alteraciones funcionales de los granulocitos neutrofilos en un joven neutropenico de raza negra 151
WT1 GENE EXPRESSION IS SIGNIFICANTLY INHIBITED BY VORINOSTAT AND BORTEZOMIB IN MYELOPROLIFERATIVE/MYELODISPLASTIC DISEASES 151
1,25-Dihydroxyvitamin D3-mediated inhibition of human leukemic B cell precursors 150
Skin and stomach graft versus host disease after syngeneic BMT in CML: A case report., LEUKEMIA RESEARCH,pp 00,tot.pag 00,tot. autori 7,2007 150
EFFICACY OF FLUDARABINE, CYCLOPHOSPHAMIDE, RITUXIMAB (FCR) REGIMEN FOL- LOWED BY ALEMTUZUMAB AS IN VIVO PURGING TOOL FOR PATIENTS WITH ADVANCED CHRONIC LYMPHOCYTIC LEUKEMIA 150
Radioimmunotherapy with radretumab in patients with relapsed hematologic malignancies. 150
Multidrug Resistance and electromagnetic fields 150
Binding of GC (VDBP) to membranes of human B lymphocytes following stripping of extant protein. 149
A case of Staphylococcal toxic shock syndrome with expansion of TCR alphaBeta+, CD4/CD8 double negative lymphocytes 149
CD57 and γδ T‐cell receptor expression in nodal metastatic spread of melanoma 149
Processing large-diameter poly(L-lactic acid) microfiber mesh/mesenchymal stromal cell constructs via resin embedding: an efficient histologic method 149
HOX and TALE signatures specify human stromal stem cell populations from different sources. 149
Mesangiogenic Progenitor Cells Derived from One Novel CD64brightCD31brightCD14neg Population in Human Adult Bone Marrow 149
A simple prognostic scoring system for newly diagnosed cytogenetically normal acute myeloid leukemia: retrospective analysis of 530 patients. 148
Leukocyte migration inhibitory activity in the serum of patients affected by Hodgkin's disease and other immunoproliferative diseases 147
Unexpected cardiotoxicity in haematological bortezomib treated patients 146
Comment on "Germinal center helper T cells are dual functional regulatory cells with suppressive activity to conventional CD4+ T cells" 146
Low-dose ARA-C and 1(OH) D3 administration in acute non lymphoid leukemia: pilot study. 145
Reversing of chlorambucil resistance by ethacrynic acid in a B-CLL patient 145
Use of Autologous Human mesenchymal Stromal Cell/Fibrin Clot Constructs in Upper Limb Non-Unions: Long-Term Assessment 145
Response-guided ABVD chemotherapy plus involved-field radiation therapy for intermediate-stage Hodgkin lymphoma in the pre-positron emission tomography era: a Gruppo Italiano Studio Linfomi (GISL) prospective trial. 145
Phenotypic markers in chronic lymphocytic leukemia. 144
Expression of MDR1, MRP, TOPOISOMERASE-IIa, TOPOISOMERASE-IIb and GSTp in acute leukemias. 144
CD57+ T lymphocytes and functional immune deficiency 144
Enhancement of neurite outgrowth in neuronal-like cells following boron nitride nanotube-mediated stimulation 144
90y Ibritumomab Tiuxetan as Initial Treatment for Follicular Lymphoma (ZEUS Protocol). An Italian Cooperative Study Group 143
VDTPACE As Salvage Therapy For Heavily Pretreated MM Patients 143
Vitamin D binding protein is produced by human monocytes 142
Bone tissue engineering: natural origination or synthetic polymeric scaffolds? 142
Association of the hOCT1/ABCB1 genotype with efficacy and tolerability of imatinib in patients affected by chronic myeloid leukemia 142
Expression of p170 protein in multiple myeloma : a clinical study 141
Thrombocytopenic purpura: an unusual complication of eradication therapy for Helicobacter pylori 141
Association of PIM gene translocation and TELAML1 rearrangement., LEUKEMIA RESEARCH,vol. Leuk Res. 2007 Dec;31(12):1761-2 141
A PRACTICAL APPROACH TO THERAPEUTIC DRUG MONITORING OF IMATINIB IN PATIENTS AFFECTED BY CHRONIC MYELOID ELEUKEMIA. THE TIKLET PROTOCOL. 141
Glycosylated or non-glycosylated G-CSF differently influence human granulocyte functions through RhoA 141
Immunomodulators and enzymes of purine metabolism in human lymphocytes 140
CD8 expression in B-cell non-Hodgkin's lymphomas. 140
Polymorphisms in regulators of xenobiotic transport and metabolism genes PXR and CAR do not affect multiple myeloma risk: a case-control study in the context of the IMMEnSE consortium. 140
INTRA-LYMPHOCYTIC ADENOSINE-DEAMINASE AND PURINE NUCLEOSIDE PHOSPHORYLASE-ACTIVITY IN CHRONIC LYMPHOCYTIC-LEUKEMIA - EFFECT OF THYMOSTIMULIN 139
PS-341 (Bortezomid) inhibits both proliferation of megakaryoblastic cells in vitro and MK colonies production in patients affected by idiopathic myelofibrosis 139
Mesodermal progenitor cells (MPCs) differentiate into mesenchymal stromal cells (MSCs) by activation of Wnt5/calmodulin signalling pathway. 139
Type 2 diabetes-related variants influence the risk of developing multiple myeloma: results from the IMMEnSE consortium. 139
Adenosine deaminase activity in human cord blood lymphocyte subpopulations. 138
Totale 19.084
Salva come PNG Salva come JPEG
Categoria #
all - tutte 171.632
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 171.632
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20205.853 0 0 0 0 0 1.122 1.216 768 1.011 662 868 206
2020/20214.900 436 200 325 236 512 202 412 450 406 364 427 930
2021/20227.290 157 425 209 573 1.355 935 183 325 344 183 562 2.039
2022/20238.835 1.199 1.185 605 824 951 1.185 82 709 1.397 40 582 76
2023/20249.683 930 766 832 445 993 1.131 214 175 85 3.378 132 602
2024/20255.246 68 704 138 1.187 1.827 1.322 0 0 0 0 0 0
Totale 67.693